Ulisse Biomed Revolutionizes Global Diagnostics with Real-Time Genetic Analysis

Ulisse Biomed is a healthcare biotech company that operates in the field of diagnostics and therapeutics in the Area Science Park of Basovizza (Trieste). There, in the Scientific and Technological Research Area of ​​Trieste that extends for 80 thousand square meters, thanks to a collaboration with Johns Hopkins University and the Gates Foundation, a project against malaria has started and has extended to Cameroon.

The real strength of this important initiative? The technology, which allows the 3 institutes located in geographical areas even more than 9,000 kilometers apart to compare themselves on medical research in real time. A system coined in Italy, in the incubator of Trieste, where Ulisse Biomed is based, which is called “Hyris System” and allows, in fact, to diagnose in real time the resistance of mosquitoes to insecticides and examine them. Nicola Basile , CEO of Ulisse Biomed, explained how it works in detail.

Ulisse Biomed: From the study of the Papilloma virus to malaria

“Ulisse Biomed was actually born from a project linked to the Papilloma virus , for the study of some pathologies related to the female intimate sphere,” explained Nicola Basile. After the one and a half million euro seed round between 2014 and 2015, led by Copernico Innovazione, the company opened its laboratory in Trieste and filed the first patent on NanoHybrid. Subsequently, Ulisse Biomed obtained the necessary certification to produce CE-IVD (In Vitro Diagnostic) medical devices and started a collaboration with the Institute of Human Virology.

“Then we obtained other collaborations with important pharmaceutical companies and not only: the history of this company evolved in the development of other reagent technologies, up to the integration with Hyris, concluded in 2023, downstream of a process started a year earlier, which led to the development of Hyris System, the hardware and software platform that we use today to conduct genetic analyses. Since 2021, Ulisse Biomed has been listed on Euronext Growth in Milan,” explained the Ulisse Biomed CEO.

Coming to the present day, the CEO explains how the collaboration with John Hopkins University and some health districts in Cameroon was founded, thanks to which he is able to read the results of the analyses conducted on malaria in real time.

“The connection with John Hopkins University was born thanks to Hyris system, our platform that can perform genetic analyses distributed throughout the world and allows the performance of diagnostic tests with real-time data monitoring thanks to a cloud software. Hyris has always been in close contact with the North American world and this has allowed us to enter the John Hopkins network as potential partners.”

Technology, the real strength of the Ulisse Biomed project

“The cloud is our center but also the ease of access to the hardware makes the difference – says Nicola – This is especially evident in the Cameroonian districts, where the accessibility conditions, not only health-related, are very difficult. With Hyris System, once the test, from Cameroon, is loaded onto the machine, in 2 hours from Baltimore they see the results. And to think that the technologies used up to now required up to 6 months of processing since the samples had to be collected in remote areas and then transported to centralized laboratories.”

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us